TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
News Nov 12, 2008
TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.
"We are pleased to announce the sale of our genetics program to our long-time partner, Eisai," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The sale of this asset furthers our transition to a development-only company and enables us to focus our resources on advancing our clinical stage assets: tezampanel, NGX426 and NGX267. As a leader in treating Alzheimer's disease we believe Eisai is well positioned to capitalize on the discoveries from the genetics program."
The genetics program is one of two TorreyPines discovery programs focused on Alzheimer's disease, the other being a gamma secretase modulator (GSM) program.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.